PET/CT in leukemia: utility and future directions.

IF 1.3 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear Medicine Communications Pub Date : 2024-04-22 DOI:10.1097/MNM.0000000000001846

Akram Al-Ibraheem, Sudqi Allouzi, A. Abdlkadir, Miriam Mikhail-Lette, K. Al-rabi, M. Ma'koseh, Peter Knoll, Zaid Abdelrhman, Omar Shahin, Malik E. Juweid, Diana Paez, E. Lopci

{"title":"PET/CT in leukemia: utility and future directions.","authors":"Akram Al-Ibraheem, Sudqi Allouzi, A. Abdlkadir, Miriam Mikhail-Lette, K. Al-rabi, M. Ma'koseh, Peter Knoll, Zaid Abdelrhman, Omar Shahin, Malik E. Juweid, Diana Paez, E. Lopci","doi":"10.1097/MNM.0000000000001846","DOIUrl":null,"url":null,"abstract":"2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease. However, its role in various clinical scenarios in leukemia remains unacknowledged. Despite their less common use, some novel PET/CT radiotracers are being researched for potential use in specific scenarios in leukemia patients. Therefore, the objectives of this review are to provide a thorough assessment of the current applications of [18F]FDG PET/CT in the staging and monitoring of leukemia patients, as well as the potential for an expanding role of PET/CT in leukemia patients.","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine Communications","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MNM.0000000000001846","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease. However, its role in various clinical scenarios in leukemia remains unacknowledged. Despite their less common use, some novel PET/CT radiotracers are being researched for potential use in specific scenarios in leukemia patients. Therefore, the objectives of this review are to provide a thorough assessment of the current applications of [18F]FDG PET/CT in the staging and monitoring of leukemia patients, as well as the potential for an expanding role of PET/CT in leukemia patients.

查看原文本刊更多论文

PET/CT 在白血病中的应用：实用性和未来方向。

2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography（[18F]FDG PET/CT）已被证明是检测和评估血液系统恶性肿瘤，尤其是淋巴瘤的灵敏方法。白血病发病率和死亡率的上升引起了人们的极大关注。通过利用全身成像，[18F]FDG PET/CT 可对整个骨髓进行全面评估，补充活检样本提供的有限信息。在这方面，[18F]FDG PET/CT 能够评估各种类型的白血病。[18F]FDG PET/CT 在评估白血病向骨髓外扩散、跟踪疾病复发、识别里氏转化以及评估与急性移植物抗宿主疾病相关的炎症活动方面非常有效。然而，它在白血病各种临床情况中的作用仍未得到认可。尽管PET/CT放射性核素的使用并不普遍，但一些新型的PET/CT放射性核素正在被研究用于白血病患者的特定情况。因此，本综述的目的是全面评估[18F]FDG PET/CT 目前在白血病患者分期和监测中的应用，以及 PET/CT 在白血病患者中发挥更大作用的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear Medicine Communications 医学-核医学

CiteScore

2.20

自引率

6.70%

发文量

212

审稿时长

3-8 weeks

期刊介绍： Nuclear Medicine Communications, the official journal of the British Nuclear Medicine Society, is a rapid communications journal covering nuclear medicine and molecular imaging with radionuclides, and the basic supporting sciences. As well as clinical research and commentary, manuscripts describing research on preclinical and basic sciences (radiochemistry, radiopharmacy, radiobiology, radiopharmacology, medical physics, computing and engineering, and technical and nursing professions involved in delivering nuclear medicine services) are welcomed, as the journal is intended to be of interest internationally to all members of the many medical and non-medical disciplines involved in nuclear medicine. In addition to papers reporting original studies, frankly written editorials and topical reviews are a regular feature of the journal.